Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
HCL-C
MCID: CLS052
MIFTS: 27

Classic Hairy Cell Leukemia (HCL-C)

Categories: Blood diseases, Cancer diseases, Rare diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Classic Hairy Cell Leukemia

About this section

MalaCards integrated aliases for Classic Hairy Cell Leukemia:

Name: Classic Hairy Cell Leukemia 58
Leukemic Reticuloendotheliosis 58
Hairy Cell Leukemia 71
Hcl-C 58

Characteristics:

Orphanet epidemiological data:

58
classic hairy cell leukemia
Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (United States); Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare haematological diseases


External Ids:

MESH via Orphanet 44 D007943
ICD10 via Orphanet 33 C91.4
UMLS via Orphanet 72 C0023443
Orphanet 58 ORPHA58017
UMLS 71 C0023443
Sources

Summaries for Classic Hairy Cell Leukemia

About this section
MalaCards based summary : Classic Hairy Cell Leukemia, also known as leukemic reticuloendotheliosis, is related to intrapelvic lymph node leukemic reticuloendotheliosis and reticuloendotheliosis, x-linked. An important gene associated with Classic Hairy Cell Leukemia is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase). The drugs Simvastatin and Hypolipidemic Agents have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells.

Sources

Related Diseases for Classic Hairy Cell Leukemia

About this section

Diseases related to Classic Hairy Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 27)
# Related Disease Score Top Affiliating Genes
1 intrapelvic lymph node leukemic reticuloendotheliosis 12.6
2 reticuloendotheliosis, x-linked 11.1
3 splenomegaly 10.5
4 hairy cell leukemia 10.5
5 thrombocytopenia 10.4
6 leukemia, chronic lymphocytic 10.3
7 hypersplenism 10.3
8 monocytic leukemia 10.3
9 granulocytopenia 10.3
10 lymphoma 10.2
11 vasculitis 10.2
12 pancytopenia 10.2
13 triiodothyronine receptor auxiliary protein 10.1
14 mycosis fungoides 10.1
15 acute leukemia 10.1
16 lymphadenitis 10.1
17 gaucher's disease 10.1
18 hepatitis 10.1
19 skin disease 10.1
20 toxoplasmosis 10.1
21 48,xyyy 10.1
22 mycobacterium kansasii 10.1
23 cytomegalovirus infection 10.1
24 nephronophthisis 1 10.0
25 lymphoproliferative syndrome 10.0
26 neutropenia 10.0
27 leukemia 10.0

Graphical network of the top 20 diseases related to Classic Hairy Cell Leukemia:



Diseases related to Classic Hairy Cell Leukemia
Sources

Symptoms & Phenotypes for Classic Hairy Cell Leukemia

About this section
Sources

Drugs & Therapeutics for Classic Hairy Cell Leukemia

About this section

Drugs for Classic Hairy Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 260)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4 79902-63-9 54454
2 Hypolipidemic Agents Phase 4
3 Lipid Regulating Agents Phase 4
4 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
5 Anticholesteremic Agents Phase 4
6 Omega 3 Fatty Acid Phase 4
7
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
8
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
9
Ofloxacin Approved Phase 3 82419-36-1 4583
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
Dalteparin Approved Phase 3 9005-49-6
12
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
13
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
14
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
15
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
18
Tazobactam Approved Phase 3 89786-04-9 123630
19
Vancomycin Approved Phase 3 1404-90-6 14969 441141
20
Piperacillin Approved Phase 3 66258-76-2 43672
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
22
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
23
Captopril Approved Phase 3 62571-86-2 44093
24
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
25
Ribavirin Approved Phase 3 36791-04-5 37542
26
Palivizumab Approved, Investigational Phase 3 188039-54-5
27
Acyclovir Approved Phase 3 59277-89-3 2022
28
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
29
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
30
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
31
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
32
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
33
Polyestradiol phosphate Approved Phase 3 28014-46-2
34
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
35
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
36 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
37 Anesthetics, Dissociative Phase 3
38 Immunoglobulins Phase 3
39 Antibodies Phase 3
40 Antibodies, Monoclonal Phase 3
41 Heparin, Low-Molecular-Weight Phase 3
42 Excitatory Amino Acid Antagonists Phase 3
43 Narcotics Phase 3
44 Analgesics Phase 3
45 Analgesics, Opioid Phase 3
46 Hematinics Phase 3
47 Cytochrome P-450 Enzyme Inhibitors Phase 3
48 Antiparasitic Agents Phase 3
49 Antiprotozoal Agents Phase 3
50 ferric gluconate Phase 3

Interventional clinical trials:

(show top 50) (show all 178)
# Name Status NCT ID Phase Drugs
1 An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate Simvastatin 20 mg Plus Omacor 4g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia Unknown status NCT00678743 Phase 4 Omacor + simvastatin
2 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
3 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3 2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
5 A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia Completed NCT01829711 Phase 3 Moxetumomab pasudotox;IV Bag Protectant for Moxetumomab pasudotox
6 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
7 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
8 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
9 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
10 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
11 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
12 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
13 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
14 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
15 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
16 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
17 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
18 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
19 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
20 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
21 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
22 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 Therapy Optimisation for the Treatment of Hairy Cell Leukemia Recruiting NCT02131753 Phase 2, Phase 3 Cladribine s.c. injection, HCL treatment
24 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
25 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
26 Rituximab (IDEC-C2B8, Mabthera) in Patients With Hairy Cell Leukemia Relapsing After Treatment With 2-Chlorodeoxyadenosine (CDA) Completed NCT00003757 Phase 2
27 Phase II Trial Of BL22 Immunotoxin In Hairy Cell Leukemia Completed NCT00074048 Phase 2 BL22
28 A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia Completed NCT00001567 Phase 2 Roferon-A
29 Study on the Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia Completed NCT02157181 Phase 2 2CdA +/- Rituximab
30 Adoptive Immunotherapy of Epstein Barr Virus Induced Lymhoproliferative Disease. A Comparison of Allogeneic and Autologous Lymphocyte Responses ex Vivo and Use of Highly Selected Reactive Cells as an Alternative to Chemotherapy in Vivo. Completed NCT00005606 Phase 2
31 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
32 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
33 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
34 A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
35 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
36 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
37 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
38 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
39 Open Label Multicenter Study of Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) Completed NCT01610180 Phase 2 Eltrombopag Olamine
40 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
41 A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
42 Phase II Study of Allogeneic Transplant of Hematopoietic Stem Cells From a Compatible Family Donor in the Treatment of Patients Over 55 Years With Hematological Malignancies Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
43 A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
44 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
45 A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
46 A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
47 A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia Completed NCT00077922 Phase 2 LMB-2
48 Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation Completed NCT00003887 Phase 2
49 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
50 Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00003408 Phase 2

Search NIH Clinical Center for Classic Hairy Cell Leukemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cladribine
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Sources

Genetic Tests for Classic Hairy Cell Leukemia

About this section
Sources

Anatomical Context for Classic Hairy Cell Leukemia

About this section

MalaCards organs/tissues related to Classic Hairy Cell Leukemia:

40
Bone, Bone Marrow, T Cells, B Cells, Monocytes, Spleen, Liver
Sources

Publications for Classic Hairy Cell Leukemia

About this section

Articles related to Classic Hairy Cell Leukemia:

(show top 50) (show all 142)
# Title Authors PMID Year
1
A BRAF Negative Classic Hairy Cell Leukemia Patient in Long Lasting Complete Remission after Rituximab and Pentostatin. 61
32539314 2020
2
BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. 61
31740808 2020
3
Genome-wide promoter methylation of hairy cell leukemia. 61
30723113 2019
4
Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib. 61
30630817 2019
5
[Hairy cell leukemia complicated by bone marrow necrosis following cladribine administration]. 61
31281144 2019
6
Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. 61
29955146 2018
7
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. 61
27903528 2017
8
Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7):609-630. 61
27013208 2016
9
Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option. 61
27429657 2016
10
BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. 61
26350141 2015
11
Current therapeutic options in hairy cell leukemia. 61
24971416 2014
12
How I treat hairy cell leukemia. 61
19843881 2010
13
Hairy cell leukemia variant developing in a background of polycythemia vera. 61
12683904 2003
14
Atypical hairy cell leukemia. 61
11079033 2000
15
Treatment of hairy cell leukemia-variant with cladribine. 61
10706459 1999
16
[A 65 year-old man with leukemic reticuloendotheliosis, fever of unknown origin and multiorgan failure]. 61
9774891 1998
17
Fine needle aspiration of the spleen in hairy cell leukemia. A case report. 61
7631555 1995
18
[Outline of proliferative disorders in the mononuclear phagocytic system--monocytic leukemia, myelomonocytic leukemia, leukemic reticuloendotheliosis]. 61
2733152 1989
19
Antibodies to porcine uteroferrin used in measurement of human tartrate-resistant acid phosphatase. 61
3117432 1987
20
[Hairy cell leukemia (leukemic reticuloendotheliosis). A diagnostic challenge for both the clinician and pathologist]. 61
3603497 1987
21
Hairy cell leukemia in pregnancy: a case report. 61
3799754 1987
22
Cutaneous leukocytoclastic vasculitis complicating hairy cell leukemia (leukemic reticuloendotheliosis). 61
3740885 1986
23
Transformed T lymphocytes infected by a novel isolate of human T cell leukemia virus type II. 61
2998509 1985
24
Prognostic factors in hairy cell leukemia (leukemic reticuloendotheliosis). 61
6692307 1984
25
[Monolayer culture of bone marrow and splenic fibroblasts in lymphoproliferative diseases]. 61
6548048 1984
26
Leukocytoclastic vasculitis in hairy cell leukemia (leukemic reticuloendotheliosis). 61
6651310 1983
27
The human T-cell leukemia/lymphoma virus associated with American adult T-cell leukemia/lymphoma. 61
6223675 1983
28
Phenotype of the hairy cells of leukemic reticuloendotheliosis defined by monoclonal antibodies. 61
6340460 1983
29
[A case of T-cell malignancy with clinical manifestations of chronic leukemic reticuloendotheliosis]. 61
6984088 1982
30
Second malignancies in hairy cell leukemia (leukemic reticuloendotheliosis). 61
6291381 1982
31
[Leukemic reticuloendotheliosis. Clinical entity and therapeutic problems]. 61
7146713 1982
32
A case of leukemic reticuloendotheliosis responding to oxymetholone. 61
7093884 1982
33
Bone involvement in hairy-cell leukemia. 61
7066868 1982
34
[Propedeutic and therapeutic considerations on leukemic reticuloendotheliosis. Report of a case]. 61
7345533 1981
35
Comparison of the tartrate-resistant acid phosphatase in Gaucher's disease and leukemic reticuloendotheliosis. 61
6794944 1981
36
Sideroblastic anemia associated wtih hairy cell leukemia. 61
7248902 1981
37
Beneficial effect of hepatitis in leukemic reticuloendotheliosis. 61
7247595 1981
38
Infections in hairy cell leukemia (leukemic reticuloendotheliosis). 61
7226028 1981
39
Comparison of tartrate-resistant acid phosphatase in normal mouse tissues to that in the reticulum cells of leukemic reticuloendotheliosis. 61
7226020 1981
40
[Hairy cell leukemia (leukemic reticuloendotheliosis) (author's transl)]. 61
7025110 1981
41
Radiation exposure as a possible etiologic factor in hairy cell leukemia (leukemic reticuloendotheliosis). 61
7417955 1980
42
A role for radiation in the treatment of hairy cell leukemia complicated by massive lymphadenopathy: a case report. 61
6154523 1980
43
Hairy cell leukemia with acquired dyserythropoiesis. 61
7362394 1980
44
Immunological and biochemical evidence for identity of tartrate-resistant isoenzymes of acid phosphatases from human serum and tissues. 61
6767568 1980
45
[Interaction of cells of hairy cell leukemia (leukemic reticuloendotheliosis) with colloidal iron]. 61
7376474 1980
46
Leukemic reticuloendotheliosis (hairy cell leukemia): a review of the evidence concerning the immunology and origin of the cell. 61
7015022 1980
47
Leukopheresis therapy of leukemic reticuloendotheliosis (hairy cell leukemia). 61
465739 1979
48
Hairy cell leukemia (leukemic reticuloendotheliosis): chemotherapy for splenectomy failures. 61
454837 1979
49
The effectiveness of rubidazone in hairy cell leukemia (leukemic reticuloendotheliosis). 61
454838 1979
50
Treatment of hairy cell leukemia (leukemic reticuloendotheliosis) II. Chlorambucil therapy in postsplenectomy patients with progressive disease. 61
454839 1979
Sources

Variations for Classic Hairy Cell Leukemia

About this section
Sources

Expression for Classic Hairy Cell Leukemia

About this section
Search GEO for disease gene expression data for Classic Hairy Cell Leukemia.
Sources

Pathways for Classic Hairy Cell Leukemia

About this section
Sources

GO Terms for Classic Hairy Cell Leukemia

About this section
Sources

Sources for Classic Hairy Cell Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....